Table 3 Effect of addition of MRA on final visit renal function and urinary protein/albumin excretion
Variable | Measurement | No. of study groups | No. patients in intervention | No. patients in placebo/control | Effect size (95Â % CI) | I2 (p value) |
|---|---|---|---|---|---|---|
Creatinine (μmol/L) | Final visit | 16 | 601 | 595 | 3.83 (−2.14, 9.79) | 50.4 % (0.011) |
Creatinine Clearance (ml/min) | Final visit | 6 | 132 | 130 | −2.51 (−7.05, 2.04) | 0.0 % (0.599) |
eGFR (ml/min/1.73 m2) | Final visit | 13 | 626 | 617 | −2.71 (−4.85, −0.57) | 0.0 % (0.727) |
GFR (any measure) | Final visit | 17 | 692 | 682 | −3.15 (−5.36, −0.95) | 0.0 % (0.790) |
Urinary ACR (mg/mmol) | Final visit | 7 | 355 | 351 | −10.91 (−26.15, 4.32) | 83.4 % (0.000) |
Urinary PCR (g/g creatinine) | Final visit | 4 | 146 | 150 | −0.91 (−1.35, −0.46) | 58.4 % (0.065) |
24 h urinary albumin excretion (mg/24 h) | Final visit | 6 | 151 | 155 | −332.91 (−624.80, −41.02) | 66.5 % (0.011) |
Change from baseline | 3 | 90 | 94 | −292.23 (−422.19, −162.27) | 0.0 % (0.606) | |
24 h urinary protein excretion (g/24 h) | Final visit | 2 | 124 | 121 | −0.41 (−0.90, 0.09) | 77.1 % (0.037) |